Novel mPGES-1 inhibitor, vipoglanstat, shows no benefit for systemic sclerosis-related Raynaud’s phenomenon in clinical trial
Methylprednisolone fails to show benefit in very early systemic sclerosis: ‘Hit Hard and Early’ trial results
Meta-analysis corroborates the clinical use of cevimeline in alleviating xerostomia in Sjögren’s syndrome
